XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenue:    
Total revenue $ 84,685 $ 72,049
Operating expenses:    
Research and development 18,524 18,711
Sales and marketing 22,991 19,830
General and administrative 22,769 30,140
Litigation settlement expense 5,360 0
Total operating expenses 98,059 94,615
Loss from operations (13,374) (22,566)
Other income:    
Interest income, net 2,784 2,885
Other income (expense), net 295 (290)
Total other income 3,079 2,595
Loss before income taxes (10,295) (19,971)
Income tax (expense) benefit (58) 83
Net loss $ (10,353) $ (19,888)
Net loss per share    
Basic (in dollars per share) $ (0.19) $ (0.38)
Diluted (in dollars per share) $ (0.19) $ (0.38)
Weighted-average shares used to compute net loss per share:    
Basic (in shares) 55,262,459 51,692,358
Diluted (in shares) 55,262,459 51,692,358
Testing services revenue    
Revenue:    
Total revenue $ 61,921 $ 53,837
Operating expenses:    
Cost of testing services, product, digital, and other 15,113 13,632
Product revenue    
Revenue:    
Total revenue 10,810 8,594
Operating expenses:    
Cost of testing services, product, digital, and other 5,586 5,344
Patient and digital revenue    
Revenue:    
Total revenue 11,954 9,618
Operating expenses:    
Cost of testing services, product, digital, and other $ 7,716 $ 6,958